

Sanofi – Discontinuation of Adlyxin[®] (lixisenatide)

- On January 1, 2023, [Sanofi announced](#) that [Adlyxin \(lixisenatide\)](#) will no longer be available in the U.S. market.
 - The discontinuation was a business decision and was not due to safety or efficacy issues.
- Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Product Description	NDC#
Adlyxin (lixisenatide) 50 mcg/mL, 3 mL single-patient-use prefilled pen	0024-5741-01
Adlyxin (lixisenatide) 100 mcg/mL, 3 mL single-patient-use prefilled pen	0024-5740-00

- Other injectable GLP-1 agonists indicated for the treatment of type 2 diabetes include [Trulicity[®] \(dulaglutide\)](#), [Byetta[®] \(exenatide\)](#), [Bydureon BCise[®] \(exenatide extended-release\)](#), [Victoza[®] \(liraglutide\)](#), [Mounjaro[™] \(tirzepatide\)](#), and [Ozempic[®] \(semaglutide\)](#). [Soliqua[®] 100/33 \(insulin glargine and lixisenatide\)](#) will continue to be available.